A simple, efficient and reproducible method to transduce proteins into mammalian cells has not been established. Here we describe a novel protein transduction method based on a lentiviral vector. We have developed a method to package several thousand foreign protein molecules into a lentivirus-like nanoparticle (LENA) and deliver them into mammalian cells. In this proof-of-concept study, we used b-lactamase (BlaM) as a reporter molecule. The amino-terminus of BlaM was fused to the myristoylation signal of lyn, which was placed upstream of the amino-terminus of Gag (BlaM-gag-pol). By co-transfection of plasmids encoding BlaM-gag-pol and vesicular stomatitis virus-G (VSV-G) into 293T cells, LENA were produced containing BlaM enzyme molecules as many as Gag per capsid, which has been reported to be B5000 molecules, but lacking the viral genome. Infection of 293T and MT-4 cells by VSV-G-pseudotyped BlaM-containing LENA led to successful transduction of BlaM molecules into the cell cytoplasm, as detected by cleavage of the fluorescent BlaM substrate CCF2-AM. LENA-mediated transient protein transduction does not damage cellular DNA, and the preparation of highly purified protein is not necessary. This technology is potentially useful in various basic and clinical applications. Gene Therapy (2011) 18, 936-941;
INTRODUCTION
When viruses infect cells the viral contents are released. A virus can, therefore, be considered as a protein transduction vehicle into a target cell if a large number of foreign proteins are packaged per virion. A lentiviral vector, approved for human gene therapy, 1 has been produced by transfecting 293T cells with four plasmids: the gene transfer vector that provides the viral genome packaged into the virion, and three plasmid vectors, each expressing gag-pol, rev or the vesicular stomatitis virus-G (VSV-G) genome. [2] [3] [4] The gag-pol expression vector produces Gag and Gag-pol in a ratio of B20:1 because of the frameshift signal positioned between the gag and pol open reading frames. 5 Gag (Pr55 Gag ) is a viral structural protein that traffics to the plasma membrane aided by its amino-terminal myristoyl group, and self-oligomerizes at the plasma membrane to form a spherical structure. 6 The expression of Gag alone leads to the production of an enveloped virus-like particle (VLP) of B100 nm in diameter, consisting of B5000 Gag molecules. 7 When the gag-pol expression vector is used to produce VLP, both Gag and Gag-pol proteins, a total of 5000 molecules, 7 form the lentiviral nanoparticles in which approximately one-twentieth of the VLP-forming protein is Gag-pol. 5 The VLP produced by the gag-pol expression vector undergoes maturation whereby Gag is processed by the protease made from Pol. Gag is cleaved into p17 MA , p24 CA and other smaller fragments. This changes the shape of the VLP core from doughnut shape to bullet shape, as visualized by electron microscopy. Mediated by VSV-G, the mature VLP envelope fuses to the cell membrane more efficiently than the immature VLP. 8 In accordance with this process, if a foreign protein is fused to lentiviral Gag, a large number of foreign proteins should be transduced into mammalian cells. In this work, the lentiviral vector has been engineered to achieve this goal.
By co-transfecting two plasmid vectors, each expressing gag-pol or VSV-G, the lentivirus-like nanoparticles (LENA) can be produced with a VSV-G envelope (Figure 1a ). These particles undergo maturation, and should be highly competent for promoting fusion of LENA envelope to the cell membrane. The VSV-G-pseudotyped LENA should be capable of releasing viral content into the target cells. We have named this process 'pseudoinfection' because it mimics viral infection, but is not accompanied by integration of the viral genome into chromosomal DNA.
We have previously shown that substitution of the human immunodeficiency virus type 1 (HIV-1) Gag myristoylation signal with the phospholipase C-d 1 pleckstrin homology (PH) domain, or attachment of heterologous myristoylation signals to the amino-terminus of Gag, increases the production of lentiviral vector. 9, 10 In these studies we used the human codon-optimized gag-pol to maximize viral protein synthesis. The infectivity of these pseudovirions was comparable with that of the wild-type (WT) counterpart. This is noteworthy because modification of Gag often results in reduction of viral productivity and infectivity. 11, 12 It has been reported recently that a protein transduction using murine leukemia virus is achievable by embedding a foreign gene in gag. However, the viral productivity and infectivity need to be improved by WT Gag-pol provided in trans upon viral production. These data suggest that by fusing a foreign protein to the amino-terminus of Gag and providing a membrane-targeting signal, it is possible to produce a high-titer, uniform, foreign proteincontaining LENA without the need to co-transfect the WT Gag-pol expression plasmid. We tested whether the VSV-G-pseudotyped LENA could serve as a protein transduction vehicle for mammalian cells using b-lactamase (BlaM) as a reporter.
RESULTS AND DISCUSSION
BlaM was chosen as reporter molecule because mammalian cells do not have BlaM activity. Also, a cell-membrane-permeable BlaM substrate is available, which can distinguish LENA content release from cellular endocytosis of LENA that can occur without membrane fusion. 13 BlaM was fused to the amino-terminus of gag-pol, and the lyn myristoylation signal was attached to the amino-terminus of BlaM (BlaM-gag-pol; Figure 1b) . The codon usage of gag-pol has been human codon optimized, but bearing the natural -1 frameshift signal at the gag-pol junction. 14 Thus, the vector provides the natural Gag to Gag-pol ratio. The BlaM-gag-pol protein was produced in 293T cells as expected (Figure 1c) . The BlaM construct produced VLP from the transfected cells, although the efficiency was less than with WT gag-pol (Figure 1c) . The processing efficacy of Gag in BlaM VLP was less efficient compared with the WT as highlighted by the absence of free matrix domain (MA) signal in BlaM VLP, which was because of the lack of HIV-1 protease recognition motif between BlaM and MA (right panel, Figure 1c ). In 293T cells transiently transfected with this plasmid, the BlaM-gag-pol fusion protein distribution was similar to that of the WT, although with some aggregation in the cytoplasm (Figure 1d ). The BlaM-gag-pol fusion protein retained enzyme activity as demonstrated by its reaction with the BlaM substrate nitrocefin, which changed from a straw color to brown when incubated with Two plasmids are transfected into 293T cells, and LENA is recovered from the culture supernatant at 48 h post-transfection. The viral protease is activated after the VLP is released from the cell, and it mediates the maturation of the particles. (b) The structure of WT gag-pol, a mutant bearing the myristoylation signal of lyn (myr lyn -gag-pol), and blaM-gag-pol. Gag is cleaved into p17 MA (MA), p24 CA (CA), nucleocapsid (NC) and other domains by the viral protease encoded in pol. In the myr lyn -gag-pol and blaM-gag-pol constructs, the Gag translational initiation site and the myristoylation target residues were mutated to leucine and alanine to minimize internal translational initiation and myristoylation. (c) Verification of protein expression and VLP production of BlaM-gag-pol construct in 293T cells by western blot analysis using anti-p24 CA and anti-p17 MA Protein transduction into 293T cells was conducted by exposing target cells to VSV-G-pseudotyped BlaM-LENA, which mimics viral infection. The success of BlaM transduction into the target cell cytoplasm was judged by using the cytoplasm-retained BlaM substrate, CCF2-AM, which yields blue fluorescence upon cleavage by BlaM enzyme activity.
The 293T cells emitted green fluorescence when they were loaded with CCF2-AM ( Figure 2, compare a vs b) . When 293T cells were transfected with expression vectors for BlaM or the BlaM-gag-pol, substrate cleavage, as demonstrated by a shift to blue fluorescence, was detected in a discrete population of cells, representing a transfection efficiency of B45% (Figures 2c and d) . These data suggest that transduced BlaM-gag-pol has BlaM activity, consistent with the results of the nitrocefin assay (Figure 1e ). When BlaM was transduced into 293T cells by VSV-G-pseudotyped BlaM-LENA, a significant shift from green to blue fluorescence was detected (63.9%, Figure 2f ). The rightward shift of the signal along the x axis suggests that almost all the cells were transduced with BlaM by BlaM-LENA. BlaM transduction was dependent on VSV-G function as CCF2-AM cleavage was not detected by LENA lacking VSV-G (Figure 2e) , and BlaM transduction was inhibited by bafilomycin A1 that blocks VSV-G-mediated membrane fusion (Figure 2 , compare g vs h). The catalytic activity was visualized under the fluorescent microscopy. In agreement with the flow cytometric analysis, almost all the substrate-loaded 293T cells exposed to BlaM-LENA became blue fluorescent in experimental conditions comparable with the above experiments, and the catalytic activity was not detected when cells were treated with bafilomycin A1 (Figure 2i ). The blue fluorescence was detected homogenously in the cell cytoplasm (Figure 2i ). These data were reproduced in human T-cell line MT-4 ( Figure 2j ). Considering the critical dependence to VSV-G, it is highly unlikely that the BlaM activity was derived from the residual DNA/lipid mixture in the LENA preparation. The BlaM-transducing unit into 293T cells was B0.8 ± 0.01Â10 9 ml À1 as estimated by the BlaM-LENA serial dilution (data not shown). Thus, 293T cells were exposed to B1000-fold excess of BlaM-LENA. We constructed GFP-PH-LENA to visualize the LENA particles (Figure 3a) . In this construct, the PH domain from phospholipase C-d 1 functions as the membrane targeting motif. 9, 10 The GFP-PH-gag-pol was distributed at cell periphery, similar to Gag-GFP (Figure 3b ). The VLP production by GFP-PH-gag-pol was verified in western blot analysis (Figure 3c ). According to the estimated molecular weight of protease-mediated cleavage products, we speculate the possible protease recognition sites within green fluorescent protein (GFP), GFP-PH junction and PH-MA junction, although we did not intentionally reconstitute the HIV-1 protease recognition sites in these positions (Figure 3c ). The GFP-encapsidated LENA preparations were spotted onto the poly-L-lysine-coated slide glass, and the captured LENA was imaged by the confocal microscopy. By counting the green fluorescent dot signals per unit area, we estimated the number of GFP-PH-LENA particles as 1.4±0.2Â10 9 ml À1 (Figure 3d) , which was similar to the BlaM-transduction unit of VSV-G-pseudotyped BlaM-LENA.
To test whether the lentivirus vector used to produce BlaM-LENA retained any viral infectivity, a lentivirus vector was produced carrying the luciferase gene, using the four plasmid system 9,10 with the BlaM-gag-pol construct, and then viral infectivity was assessed. Gene transduction by this lentiviral vector was undetectable. These data indicate that transfer to target cells by BlaM-LENA of an expressed, endogenous retroviral element from 293T cells is unlikely to occur. These data show that a protein transduction system based on LENA would have an extra level of safety compared with the protein transduction system based on a retroviral vector system. 11 Protein transduction in a broad sense, referring to the transport of protein across the cell membrane, is a useful technique in experimental molecular biology. It does not require de novo transcription and translation, and the transferred protein functions immediately after the transduction. Proteins, however, do not easily pass through the plasma membrane. Historically, microinjection, electroporation and cell-permeable peptide motifs were used to introduce proteins into cells. [15] [16] [17] These methods, however, demand a highly purified protein, technical skill or specialized, costly equipment. Also, variable results have been obtained using different proteins and target cells. The need of a highly purified protein applies to protein lipofection to yield the reproducible results. A convenient, fast, highly efficient and reproducible protein transduction method has so far remained undeveloped. Such a technique would greatly help the generation of safe, induced pluripotent stem cells. LENA production is as straightforward as co-transfecting two plasmids into 293T cells without trans-complementing the WT gag-pol expression vector, and furthermore the therapeutic protein is protected from plasma proteases by a lipid bilayer. The target cell tropism can be controlled by well-established viral pseudotype techniques. Using LENA, a substantial number of protein molecules can be packaged into the nanoparticles, and the transduction procedure is as easy as exposing mammalian cells with LENA. There is no need to prepare highly purified proteins for the LENA system. Also, target proteins are post-translationally modified in human cells, which should be better than the protein modification in non-human organisms. It should also be possible to increase the amount of protein that can be delivered into cells by concentrating the LENA preparation. Physical counting of GFP-encapsidated LENA shows that a high-titer LENA preparation was casually produced. In this study, we did not introduce protease recognition sites into myristoylation signal-BlaM or -BlaM-MA junctions. By doing so, we would have possibly liberated the foreign protein from the precursor. This could result in infectious LENA particles as the free MA is in part important for the viral infectivity. 9 Currently, few approaches are available for the incorporation of a foreign protein into retro-or lenti-viral VLP. The protein of interest Protein transduction by LENA T Aoki et al can be fused to the C-terminus of Gag or inserted into the middle of the Gag protein (for example, between the MA and CA). 11, 12 Foreign protein fusion to the C-terminus of Gag would destroy the frameshift signal required to produce Gag-pol. Thus, Pol would no longer be produced. To maintain efficient pseudoinfection, the gag-pol expression vector must be provided in trans when the VLP is produced. The latter approach often results in reduced VLP yield. Thus, again, to increase the VLP yield, the gag-pol expression vector has to be co-transfected with the plasmid encoding Gag fused to the foreign protein. Co-transfection of the gag-pol expression vector is likely to reduce the amount of foreign protein per VLP, and lower its uniformity. It is, therefore, desirable not to co-transfect with the WT gag-pol expression plasmid. Alternatively, Vpr can be used to incorporate foreign proteins into lentiviral particles. 18 Only a few dozen protein molecules, however, are packed per particle, rendering this approach of little use in protein transduction. In summary, fusion of a foreign protein to the N-terminus of Gag has the advantages of producing uniform, high-titer and membrane fusion-competent VLP without trans-complementation by WT Gag-pol.
The disadvantages of the LENA system are the susceptibility of foreign proteins to viral protease and the restriction in the molecular sizes of foreign proteins. We have succeeded in generating Gag-LacZ VLP, suggesting that the production of LENA carrying a foreign protein with a molecular weight of B100 kDa is feasible. The yield, however, of LENA gradually decreases as the molecular weight of the foreign protein increases. We did not detect proteolytic cleavage of BlaM by viral protease in LENA particles; however, when we tested the transcriptional regulator of HTLV-1 (human T-cell leukemia virus type 1), Tax, it was degraded by viral protease. To overcome these potential disadvantages, it is worth considering the use of only the minimal functional domain of a foreign protein and the destruction of potential protease recognition sites in the foreign protein without losing its function.
Lentiviral vectors have been approved for human gene therapy. 1 LENA does not contain a viral genome, and is unlikely to support the transfer of endogenous retrovirus-like elements; thus, the cellular genome is not threatened by LENA-mediated protein transduction. Thus, a major safety concern associated with retroviral or lentiviral vectors is alleviated, making LENA applicable for in vivo studies. Retroviral vectors are often used for induced pluripotent stem cell genesis. 19 However, they can damage the cellular genome, and transduced gene expression is difficult to shut off, which can lead to malignant transformation of induced pluripotent stem cells. To overcome this problem, a transient and efficient protein transduction method is needed. We believe that LENA addresses these issues. Altogether, our system has many advantages over currently available protein transduction protocols, suggesting that it should be considered for basic and clinical applications.
MATERIALS AND METHODS Plasmids
The following oligonucleotides were annealed, and cloned into the AfeI-AgeI sites of pEGFP-C2 (Clontech, Palo Alto, CA, USA) to generate the plynMyEGFP-C2: 5¢-GCTACCGGACTCAGATCTCGAGCTCAAGCTTCGAATTGC CACCATGGGATGTATTAAATCAAAAAGGAAAGACGATCCA-3¢ and 5¢-CCG GTGGATCGTCTTTCCTTTTTGATTTAATACATCCCATGGTGGCAATTCGA AGCTTGAGCTCGAGATCTGAGTCCGGTAGC-3¢. The SnaBI-EcoRI fragment from plynMyEGFP-C2 was cloned into the corresponding sites of pPH-gagpol, 9 generating plynMyGFP-gag-pol. The b-lactamase gene from pUC19 was amplified by the following primers: 5¢-ACCGGTCAATCCAGAAACGCTGGTG AAAG-3¢ and 5¢-CAATTGCCAATGCTTAATCAGTGAGGC-3¢. The AgeI-MfeI fragment of the PCR fragment was cloned into the AgeI-EcoRI sites of plynMyGFP-gag-pol, generating the pblaM-gag-pol. The expression vector for VSV-G was described previously. 20 The original codon-optimized HIV-1 gag-pol expression vector was described previously. 14 The Gag-GFP expression vector was described previously. 10 The pGFP-PH-gag-pol was constructed by inserting the NdeI-PshAI fragment from pEGFP-PLCd1 PH 21 into the corresponding sites of pPH-gag-pol. 9 pcDNA3 was obtained from Invitrogen (Tokyo, Japan).
Cells and transfection
The 293T cells, obtained from Invitrogen as 293FT cells (Invitrogen), were maintained in RPMI-1640 medium (Sigma, St Louis, MA, USA) supplemented with 10% fetal bovine serum (Japan Bioserum, Tokyo, Japan), 50 U ml -1 penicillin and 50 mg ml -1 streptomycin (Invitrogen), at 37 1C in a humidified 5% CO 2 atmosphere. Cells were transfected with DNA using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen), or calcium phosphate precipitation. To produce VSV-G-pseudotyped BlaM-LENA, equal amounts of pVSV-G and pblaM-gag-pol were transfected into 293T cells. Unenveloped BlaM-LENA was produced using pcDNA3 in place of pVSV-G.
Immunological detection
The detection of viral gene products by western blot analysis was performed as described previously, 22 except that the anti-p24 CA monoclonal antibody clone 183-H12-5C and the anti-p17 MA rabbit antiserum (NIH AIDS Research and Reference Reagent Program) were used. The immunofluorescent analysis was performed as described previously, 22 except that cells were fixed at 24 h posttransfection, and the following reagents were used: anti-p24 CA monoclonal antibody (clone 183-H12-5C), anti-mouse antibody conjugated with biotin (Invitrogen) and streptavidin conjugated with Alexa488 (Invitrogen).
Microscopy
Cells and GFP-encapsidated LENA were imaged by confocal fluorescence microscopy (LSM510 Meta 40Â NA 1.4 lens; Carl Zeiss MicroImaging Inc., Tokyo, Japan).
Colorimetric detection of BlaM activity
Transfected 293T cells grown in 6 cm dishes were lysed in 500 ml of buffer A (10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl and 0.05% IGEPAL CA-630), and then 1 ml of nitrocefin (10 mg ml -1 ; Calbiochem, San Diego, CA, USA) was added to the cell lysate. The mixture was incubated for 20 min at 37 1C.
Protein transduction
The pseudoinfection was performed as infecting cells with retroviral vectors 20 by incubating B1Â10 6 cells with 1 ml LENA-containing culture medium at 37 1C for 1-3 h in the presence of dextran (final concentration 16.25 mg ml -1 ; DEAE-Dextran chloride, molecular weight B500 kDa; ICN Biomedicals Inc., Aurora, OH, USA). The cells were assayed by flow cytometry or fluorescent microscopy after the LENA exposure. Bafilomycin A1 was purchased from Sigma.
Fluorescent detection of BlaM activity
A fluorescence-activated cell sorter Aria (Becton Dickinson, San Jose, CA, USA) was used to detect the CCF2-AM (Invitrogen) signals from 293T cells. A violet 407 nm laser was used for fluorescence activation, and BP450/40 nm and LP502 in conjunction with BP530/30 filters were used for the fluorescent signal detection of cleaved and uncleaved substrates, respectively. The CCF2-AM signals from 293T and MT-4 cells were imaged by Biorevo (BZ-9000, Keyence, Osaka, Japan) using the blue filter set (excitation, band pass filters 377/50 nm wavelength; emission, band pass 447/60 nm wavelength; dichroic mirror, 409 nm wavelength) and the green filter set (excitation, band pass filters 377/50 nm wavelength; emission, band pass 520/35 nm wavelength; dichroic mirror, 495 nm wavelength).
